madman
Super Moderator
Are we entering a new era of prostate cancer testing? In this episode, Dr. Geo speaks with Dr. Jeffrey Tosoian—urologist, researcher, and lead author behind MyProstateScore 2.0 (MPS 2.0)—a cutting-edge urine test that may outperform PSA and even MRI in identifying clinically significant prostate cancer.
Learn:
* How MPS 2.0 works and what makes it different from PSA, 4Kscore, and ExoDx
* Why MPS 2.0 offers a 95%+ negative predictive value (NPV)—helping men avoid unnecessary prostate biopsies
* When to use MRI vs. biomarker testing
* How this test may benefit Black men and those in areas with limited access to 3T MRI
* How MPS 2.0 could become a game changer for men on active surveillance
This test includes 18 prostate cancer-specific gene markers and is now available without a rectal exam. It can even be done from home. Dr. Tosoian explains everything—from clinical validation to future directions.
Ask your doctor about MPS 2.0 or visit LynxDx: https://bit.ly/4mOHQ2U to learn more.
Chapters
00:00 Better Than PSA – How MyProstateScore 2.0 with Dr. Jeffrey Tosoian
02:32 The Importance of Minimizing Unnecessary Biopsies
03:23 Advancements in Prostate Cancer Screening: MyProstateScore 2.0
03:40 The Role of PSA and Biomarkers in Prostate Cancer Detection
05:17 MRI vs. Biomarkers: Choosing the Right Diagnostic Tool
09:37 Understanding Negative Predictive Value in Prostate Cancer Tests
11:18 The Development and Validation of MyProstateScore 2.0
15:47 Practical Considerations and Real-World Application of MPS 2.0
24:24 Detailed Explanation of MyProstateScore 2.0
29:39 Advancements in Prostate Cancer Biomarkers
30:36 Understanding High-Grade Prostate Cancer
33:06 Challenges with MRI in Prostate Cancer Detection
34:37 Addressing Neuroendocrine Prostate Cancer
35:45 The Role of Lifestyle in Prostate Cancer Management
37:44 How MyProstateScore 2.0 Works
43:29 Racial Diversity and Prostate Cancer Testing
49:39 Active Surveillance and Biomarkers
